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Abstract 
 
Background:  
The five year survival for patients with glioblastoma (GBM) is low at approximately 
4.7%. Radiotherapy plus concomitant and adjuvant temozolomide (TMZ) remain the standard of 
care.  The optimal duration of therapy with TMZ is unknown, though treatment periods of six 
months, 12 months and longer have been utilized. Whether or not there is a benefit with longer 
treatment duration is controversial. This study sought to evaluate overall survival benefit of two 
years treatment. 
Methods: 
 This was a retrospective chart review of all patients diagnosed with GBM who were 
treated at a regional cancer referral center.  These patients were treated with TMZ for up to two 
years between January 1, 2002 and December 31, 2011. Survival was calculated as the time from 
initial surgical diagnosis until death. The Kaplan-Meier method with log-rank test was used to 
estimate the progression-free survival (PFS) as well as the overall survival (OS) distribution of 
patients after treatment. The results were compared to historical controls and data from previous 
clinical trials of pts treated up to one year.  
Results:  
Data from 56 patients were evaluated, the majority of whom had gross total resection and 
had external pathology review confirming the diagnosis of GBM. The OS probability was 54% 
(SE = 0.068) at one year, 28.3% (SE = 0.064) at two years, 17.8% (SE = 0.059) at three years 
and 4% (SE=0.041) at five years.  The median PFS time in this study group was eight months 
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(95% CI = 4.0 – 9.0 mo). The probability of no progression at two years was 8.6% (SE = 
0.05).  Seven patients (12.5%) were treated with TMZ for two years. The median time-to-
progression among these patients was 28 months (95% CI = 5.0-28.0). These patients showed an 
increased survival probability at three years compared to patients who did not receive the two 
year treatment of TMZ (log-rank test χ2 (1, N=56) = 19.2, p < 0.0001). 
Conclusions:  
This study suggests that there may be an advantage for a longer duration of TMZ therapy 
among patients with GBM.  In this study, treatment with TMZ for two years was associated with  
increased survival. While we consider the sample size to be too small for generalization, a 
prospective/multicenter study with a larger sample size might better evaluate the question of 
duration of TMZ therapy, particularly if both clinical and basic science data are paired.  
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Introduction 
Background and Rationale 
Brain tumors account for two percent of all cancers, but their share of cancer morbidity 
and mortality remains disproportionate due to the little advances achieved in this disease.1  
Gliomas account for more than 80% of primary central nervous system (CNS) malignancies.2 
Malignant, high grade gliomas are grade III, which include anaplastic astrocytomas, anaplastic 
oligodendrogliomas and anaplastic oligoastrocytoma, and grade IV which is glioblastoma 
(GBM). Most malignant gliomas are GBMs.  
The Central Brain Tumor Registry of the United States (CBTRUS), which is the nation's 
largest registry of primary brain tumors, reported 311,202 new cases of both malignant and 
benign brain and CNS tumors from 2005 to 2009.2 The average annual age-adjusted incidence 
rates for GBM  across 45 states with cancer registries that met or exceeded the North American 
Association of Central Cancer Registries’ (NAACCR) high quality standards for 2005 through 
2009 were 2.53 and 3.98 per 100,000 person-years for females and males, respectively.2 The 
male to female incidence rate ratio was 1.58 whereas the white to black ratio was 2.06.2 GBMs 
constituted 15.8% of all reported tumors and 54% of all gliomas. The most prevalent locations of 
all brain tumors were the frontal lobe (25.6%) and the temporal lobe (19.6%).2 CBTRUS data 
collected between 2005 and 2009 suggested the mortality rate from malignant brain and CNS 
tumors was 3.48 for females and 5.23 for males per 100,000 person-years.2 Kansas was one of 
six states where incidence was not reported in the CBTRUS report, but the mortality rates from 
malignant brain and CNS tumors were 3.93 and 6.39 per 100,000 person-years for females and 
males, respectively.2 
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The five-year survival rates for the most common malignant histologic subtypes — 
anaplastic astrocytoma and glioblastoma — are 25.9% and 4.7%, respectively.2 For all histologic 
types, pediatric and young adult populations have a better survival than do older adults. For all 
primary malignant brain tumors combined, the five year survival rate among children younger 
than age 14 is 62%, compared to 5% in adults 65 years of age and older.3 
Despite a multidisciplinary and aggressive treatment approach, GBM, the most common 
high grade malignant brain tumor, continues to have the lowest five-year survival rates among all 
human cancers.4 The median survival time from diagnosis rarely exceeds 12 months,5 and may 
even be shorter.6 The patients who survive for more than 36 months are considered long-term 
survivors.7 
Treatment of GBM is particularly challenging due to resistant tumor cells, fragility of the 
brain, and inability of most agents to cross the blood-brain barrier to reach the tumor.  
Historically, the standard therapy consists of surgical resection followed by radiotherapy.  Early 
clinical trials of the effectiveness of radiotherapy versus radiotherapy plus concomitant 
chemotherapy displayed statistically insignificant survival benefit of chemotherapy.8  However, 
more recent clinical trials and long-term analyses have identified a specific chemotherapeutic 
agent, temozolomide (TMZ), as conferring a statistically significant survival benefit when given 
concurrently with radiation therapy (as opposed to radiotherapy alone).9-11 Radiation therapy plus 
concomitant and adjuvant TMZ is currently the standard of care for treatment of patients with 
GBM.10 TMZ is a DNA alkylating agent but its way of action is still unknown. Recently, Yamaki 
et al concluded that TMZ induces TAp63 expression in GBM tissues which suppresses MYC 
transcription and inhibits GBM progression.12 
For newly diagnosed GBM, research suggests that the application of adjuvant TMZ 
9 
 
 
 
chemotherapy requires a minimum of four (three-to-four week) cycles to achieve beneficial 
treatment.10  For elderly patients diagnosed with GBM, research indicates that six (three-to-four 
week) cycles may be sufficient.13  The clinical trials which originally established the benefit of 
TMZ did so utilizing a six cycle (six months) period of treatment.9-10 More recent data suggest 
that a one year duration of adjuvant TMZ therapy may yield superior progression-free and 
overall survival without TMZ toxicity14 and this regimen is being more evaluated in a current 
clinical trial (RTOG 0525). The benefit of even longer treatment periods is unknown. Given this 
background, the optimal duration of therapy with TMZ appears to be unknown.  
Objectives 
The objective of this study was to evaluate the survival benefit, if any, of a longer 
treatment duration, with an intent to treat of two years with TMZ, given that all the other 
treatment guidelines have been followed.  
Methods 
Study Design 
The study design consisted of a chart review of patients with GBM who were treated by a 
clinical practitioner, at a cancer referral center in the Midwest, according to the latest guidelines 
with the intent to treat for two years of adjuvant therapy with TMZ. The results were compared 
to historical controls and data from previous clinical trials, where the patients were treated for up 
to one year.  
Setting 
The source of the study data is the electronic medical charts of one clinician’s patient 
population at a tertiary referral center. The registry was searched using three keywords: brain 
neoplasm, GBM, and glioblastoma. The results were then filtered according to diagnosis date so 
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that only those treated between January 1, 2002 and December 31, 2011 were displayed. 
Pertinent study variables were then extracted for those who met inclusion criteria.  
Participants 
 Patients were selected according to the following inclusion criteria: age 18 or older with a 
GBM diagnosis that received TMZ as first line chemotherapy with the intent to treat for two 
years. All eligible patients had surgery with the intent of gross resection, followed by imaging 
assessment within 24 to 48 hours from surgery and then radiation with TMZ within two to four 
weeks from diagnosis, depending on the need for rehabilitation.  
Variables  
 The continuous variables that were abstracted included age, time to progression and time 
to death. The categorical variables collected included: Karnofsky’s performance score (KPS), 
gender, region of Kansas, surgical intervention, external pathology report verification and the use 
and type of seizure medications.  
Survival was calculated as the time from surgical diagnosis until death or end of the study 
period, whichever came first. The date of death was registered and verified through hospital 
records or the obituary regardless of the cause. 
Date of diagnosis, date of progression, and date of death were compared to calculate time 
interval variables. The outcome of interest was death. Seizure medications were collected as 
possible effect modifiers. Potential confounders included type of surgical resection, inaccurate 
pathology report, and demographics. 
Data Sources and Measurements 
Data were obtained from the electronic medical records. This information was obtained from 
the patients themselves, their hospital records, and their outpatient imaging follow up results. 
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Multiple variables have been studied in the past to establish correlation with increased 
survival, some of which were at the molecular level. The only exogenous environmental 
exposure that has been linked to GBM has been ionizing radiation.15 For this reason, the region 
of Kansas where the patients lived in the last 10 years was recorded to evaluate for possible 
environmental exposures.  
Other important prognostic factors included age and KPS.16 Younger patients and those 
who had a good performance score (scored high on the Karnofsky evaluation scale) tend to have 
a better survival.9  Furthermore, Stupp et al. suggested that radiotherapy plus TMZ was 
associated with a significant improvement in median overall survival in nearly all subgroups of 
patients except in patients who underwent biopsy only and those with a poor performance 
status.9 In the current study, the performance status measurement was based on Karnofsky’s 
standardized score evaluation (Table 1). The extent of surgery was reported according to surgical 
reports and imaging evaluation after surgery. The population of interest in this study was adults 
18 years or older. 
Patients presenting with seizures needed to be started on antiepileptic therapy. 
Antiepileptic therapy might also be started as prophylaxis after brain surgery for about three 
months. While it was previously hypothesized that hepatic metabolism inducers, like first 
generation antiepileptic medications, interfere with chemotherapy agents’ efficacy, the 2010 
European Society for Medical Oncology clinical practice guidelines do not agree with this when 
it comes to temozolomide.17The data about the antiepileptic drug used were also collected for 
analysis. 
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Table 1: Karnofsky Performance Status Scale 
  
Value Level of Functional Capacity Definition 
100 Normal, no complaints, no 
evidence of disease 
Able to carry on normal activity and to work; no 
special care needed. 
90 Able to carry on normal 
activity, minor signs or 
symptoms of disease 
80 Normal activity with effort, 
some signs or symptoms of 
disease 
70 Cares for self, unable to carry 
on normal activity or to do 
active work 
Unable to work; able to live at home and care for 
most personal needs; various degrees of assistance 
needed 
60 Requires occasional assistance, 
but able to care for most needs 
50 Requires considerable 
assistance and frequent medical 
care 
40 Disabled, requires special care 
and assistance 
Unable to care for self; requires equivalent of 
institutional or hospital care; disease may be 
progressing rapidly 30 Severely disabled, 
hospitalization is indicated 
although death is not imminent 
20 Hospitalization necessary, very 
sick, active supportive 
treatment necessary 
10 Moribund, fatal processes 
progressing rapidly 
0 Dead 
 
 
Bias 
Patients with missing data about progression time and survival time were censored in the 
analysis. These missing data, had they been available, might have changed the results. To 
prevent any additional bias from censoring, we assumed that censoring was not related to any 
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adverse effect from treatment or lack of effectiveness. Misclassification bias was addressed by 
recording whether the pathology report was reviewed at an external laboratory. 
Study Size 
 The initial sample size was 211 individuals after the keywords search through the 
registry, 66 subjects with a diagnosis of GBM that were treated with TMZ were identified for the 
study. Ten subjects were censored due to missing data bringing the final study size to 56 patients. 
Statistical Methods  
All data were collected in a Microsoft Excel (version 2007) spreadsheet and analyzed using 
Statistical Analytics Software (SAS) version 9.3. Analysis was conducted to establish a 
correlation between the duration of treatment and long-term survival of those patients with 
GBMs. All tests were evaluated at a 0.05 or less level of significance.   
The response variable, overall survival from GBM, was defined as time from surgical 
resection until death from all possible causes potentially attributable to GBM. Patients who were 
still alive or for whom no definite event status (i.e. death) was ascertainable, like those lost to 
follow up, were censored for the median survival calculations. For the long-term survival 
calculation, the patients who were still alive were accounted for.  
The Kaplan-Meier method with log-rank test was used to estimate the overall survival (OS) 
distribution of patients after treatment. To adjust for potential confounding of overall survival by 
patient demographics and clinical characteristics, the Cox proportional hazards (PH) regression 
model was used to model the relationship between survival and those covariates. To assess 
model adequacy of the Cox-PH model, the proportionality assumption for this method of 
regression was evaluated. Covariates that have significant influence in determining survival from 
GBM were assessed using the stepwise method of variable selection.  
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Progression-free survival (PFS) was also evaluated. The event of interest in this respect was 
progression or recurrence of disease within two years of start of treatment. Patients who were 
lost to follow-up before their disease progressed were censored. The Kaplan-Meier method with 
log-rank test was used to estimate the progression-free survival distribution of patients after 
treatment.  
Results 
The initial search yielded 211 patients, of which 109 had GBM. Since TMZ was not first-
line treatment until around 2005,9 all patients before that period, who were treated with other 
agents, were excluded resulting in a total of 66 patients. Eleven of 66 patients were lost to follow 
up. Among these 11, time to progression was available on four of them and the date of death was 
obtained on two. One of those patients lost to follow up was known to have died, but the exact 
date of death could not be obtained.  
The study population consisted of 66 patients (25 females and 41 males) with a mean age 
at diagnosis of 60 and a standard deviation of 12.5. A total of 56 patients were included in the 
analysis because of the lack of survival time data on the other 10 patients and only seven (12.5%) 
completed two full years of TMZ (Figure 1). The median age was 62 for the whole group and 64 
for the group treated with two years of TMZ. The median Karnofsky’s performance score was 
80. 
All the patients in the study had the intent to treat for two years, but the median survival 
time was 13 months (SE= 0.068) (Figure 2). The two-year survival probability was 28.3% (SE = 
0.064) and the three-year survival probability was 17.8% (SE = 0.059). At five years, the 
computed survival probability was 4% (SE = 0.041).  
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Table 2:  Patient Characteristics 
 
2 Years 
Treatment 
Total 
Age 
20-44 2(28.6) 5(7.5) 
45-54 13(19.7) 
55-64 2(28.6) 23(34.9) 
65-74 2(28.6) 18(27.3) 
>74 1(14.2) 7(10.6) 
Gender 
Male  6 (14.6) 41 (62.1) 
Female  1 (4.0) 25 (37.9) 
Kansas Region 
Central 7 (100.0) 52 (78.8) 
Other 14 (21.2) 
Tumor localization 
Hemispherea: 
                       Right 5 (71.4) 37 (58.7) 
                       Other 2 (28.6) 26 (41.3) 
Lobeb: 
                       Frontal 4 (57.2) 26 (39.4) 
                       Temporal 1 (14.2) 21 (31.8) 
                       Other 2 (28.6) 19 (28.8) 
Treatment 
Tumor resection :  
                      Total 5 (71.4) 41 (63.1) 
                      Sub-total 2 (28.6) 20 (30.8) 
                      Biopsy 4 (6.1) 
Radiotherapy          7 (100.0) 66 (100.0) 
Progression 3 (42.9) 40 (67.8) 
External pathology review 5 (71.4) 32 (51.6) 
Antiepileptic medications 5 (71.4) 50 (75.8) 
Enzyme inducers 3(60.0) 26 (52) 
Non enzyme inducers 2(40.0) 24 (48) 
                
KPS=Karnofsky performance score, partly retrospectively evaluated. 
a The data on 3 were missing.  
b For tumors that involved more than one lobe, it was reported according to the lobe that was most affected. 
 In addition there was one tentorial, one intraventricular, one insular, one over the corpus callosum and one 
 with multiple masses on the left. They were all grouped with occipital and parietal masses under other. 
c The data on 7 was missing. Patients that were lost to follow up and no evidence of death was obtained were 
considered to not have progressed. 
d Data missing on 4. These were considered as not having had external pathology review. 
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The median time to progression was eight months (Figure 3). Patients who were treated 
with two years of TMZ (Figure 4) had a significant increase in the likelihood of survival after 
stratification (log-rank test χ2 (1, N=56) = 19.2, p < 0.0001). Survival was significantly increased 
for those who had a good KPS compared to fair (log-rank test χ2 (1, N=56) = 8.5, p = 0.0034) 
(Figure 5). Additionally, those who had a tumor located in the right cerebral hemisphere, 
compared to those with a tumor in other locations, were more likely to have increased survival 
(log-rank test χ2 (1, N=56) = 5.5, p = 0.018) (Figure 6). Patients who had successful gross 
resection had a better survival than those who had a biopsy, but only a marginal increase in 
overall survival compared to those who had a sub-total resection, with statistically insignificant 
results (log-rank test χ2 (2, N=56) =3.8, p = 0.15) (Figure 7). Those who progressed had 
decreased in survival (Figure 8). Gender (Figure 9), location (Figure 10), pathology review 
(Figure 11), and the use and type of anti-convulsive medications (Figures 12-13) appeared to 
have no effect on survival after stratification.  Age stratification (age groups: 19-44, 45-54, 55-
64, 65-74, and older than 74 years) showed increased survival with the youngest age groups 
(Figure 14), but that wasn’t statistically significant, (log-rank test χ2 (4, N=56) = 5.27, p = 0.26). 
After univariate adjustment, good KPS and the location of the tumor in the right 
hemisphere showed significant effect on survival. When multivariable analysis adjustment is 
computed only the right sided brain tumors had significant increase in survival (Table 3). Having 
the tumor located on the left side suggests increased risk of death compared to the right side 
(HR=3.077, 95% CI=1.159-8.172) (Table 3). Multivariate analysis also suggests that the risk of 
death due to GBM is considerably reduced for persons aged 45-54 compared to those aged 75 
years or older (HR= 0.161, 95% CI=0.029-0.883) (Table 3).  
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Table 3: Adjustment Table  
 
 
 
                      Univariate                       Multivariate 
 
 
Hazard Ratio 95% CI Hazard Ratio 95% CI 
Age-groups (vs. 
>74) 
    
20-44 0.301 0.060-1.521 0.407 0.038-4.366 
45-54 0.566 0.190-1.683 0.161 0.029-0.883 
55-64 0.853 0.330-2.206 0.573 0.123-2.676 
65-74 0.788 0.290-2.136 0.529 0.099-2.822 
Female  
(vs. male) 
 
 
1.346 
 
0.724-2.502 
 
0.910 
 
0.376-2.201 
KPS fair  
(vs. good) 
 
 
3.491 
 
1.394-8.746 
 
2.970 
 
0.570-15.485 
Central 
(vs. other region) 
 
 
0.514 
 
0.234-1.132 
 
0.412 
 
0.153-1.109 
Excision: sub-
total (vs. total) 
 
 
1.521 
 
0.805-2.873 
 
1.168 
 
0.531-2.569 
Excision: biopsy 
(vs. total) 
 
 
2.380 
 
0.818-6.928 
 
0.717 
 
0.099-5.917 
EIAC* 
(vs. non-EIAC) 
 
 
0.716 
 
0.373-1.376 
 
0.844 
 
0.356-2.001 
Pathology 
review: no  
(vs. yes) 
 
0.884 
 
0.482-1.623 
 
0.990 
 
0.416-2.353 
Left hemisphere 
(vs. right) 
 
 
1.989 
 
1.086-3.643 
 
3.077 
 
1.159-8.172 
Location: frontal 
(vs. temporal) 
 
 
1.208 
 
0.575-2.538 
 
1.589 
 
0.628-4.022 
Location: other 
(vs. temporal) 
 
 
1.304 
 
0.589-2.886 
 
0.970 
 
0.247-3.809 
*Enzyme inducing anticonvulsant  
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The two years treatment group analysis did suggest persistent survival advantage even 
after adjustment but that was not included in the table because of a very wide confidence interval 
due to the small sample size. 
Discussion 
 This study suggests an increase in overall survival for patients who successfully 
completed two years of TMZ therapy. Patients with a diagnosis of GBM face a particularly poor 
prognosis, and new therapies are needed. As previously noted, the optimal duration of therapy 
has not been identified. Some studies have treated patients for periods of six to 12 months.14 In 
view of the fact that, for the most part, the side effects of TMZ are well tolerated, it seemed 
reasonable to evaluate the outcome of patients who were treated for a longer period of time.  
According to population-based studies, the median age of GBM patients is 64.2 In our 
sample, both, patients who completed two years of treatment and the sample as a whole had a 
median age above 60. Age subgroup analysis suggested survival advantage for age-group 45-54 
compared to age-group older than 74, but not for the younger age-group. This is likely related to 
sample sizes in each subgroup. The number of individuals aged 45-54, and older than 74, may be 
large enough to make the analysis reasonable in these subgroups but not in the 20-44 one. Also, 
our patient population exhibited a high KPS, which has been associated with longer survival. In 
fact, all the patients who completed two years of TMZ had a good KPS score. However, 
multivariable adjustment suggested no effect of KPS on survival (Table 3). The results in that 
table were reported as confidence intervals rather than p-values because of the advantages of 
showing the direction of the effect studied and determining with more confidence the interval 
where the true value of the statistical parameter is.18 
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Table 4: List of the Long Term Survivors Studies 
 
 
Licensee: Dory Abou Jaoude; License Date: Mar 29, 2012; License Number: 2878190035955; Publication: 
Brain; Title: Long‐term survival with glioblastoma multiforme 
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Table 4 lists the reported long term survivors accounted for in the medical literature until 
2006. While some of the numbers seem intriguing, we found that a number of important features, 
primarily details regarding pathology review and treatment regimen, are missing. Inadvertent 
inclusion of patients with lower grade gliomas could skew the results toward a more favorable 
outcome. In our series, all the patients except four had evidence of additional confirmation of the 
GBM diagnosis and more than half had the results externally reviewed at another center. 
This study is consistent with the CBTRUS data regarding male to female ratio (1.64 vs 
1.58, respectively), median age, and the most prevalent locations being frontal and then temporal 
lobes. However, contrary to the previously published data, the current study suggested that good 
KPS, and total resection were not associated with improvement over fair KPS and sub-total 
resection, after multivariate adjustment. This may be accounted for by the small sample size and 
the low percentage of patients with subtotal resection and fair KPS in our patient population. In 
our series, we also observed a longer survival for those patients diagnosed with right-sided 
GBMs than those located on the left side. Whether or not this is simply a peculiar finding in a 
small study is unknown. Another potential explanation could be that the left hemisphere is the 
dominant hemisphere and where the language center is located most of the time, causing patients 
with left sided GBM to do worse because of loss of essential functions. To our knowledge, this is 
the first study that examined treatment duration of two years with temozolomide. 
Limitations: 
Several limitations exist in this study analysis. First, the sample size is too small to allow 
any generalization. However, most of the studies involving GBM and TMZ also have relatively 
small sample sizes. A prospective, multicenter study with a larger sample size might better 
evaluate the question of duration of TMZ therapy, particularly if both clinical and basic science 
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data are paired. Second, this study was a retrospective chart review with some missing data that 
may have introduced bias to the results.  
We did note that one long term survivor (81 months) in the successfully treated group 
had no external pathology review. Although a pathology review may have also confirmed the 
GBM diagnosis, there are isolated case reports about very long term survival with verified GBM 
with one patient still alive after 21 years.19 
Several genes have been implicated in GBM long term survival, mainly the MGMT 
promoter gene hypermethylation.20 More recently, over-expression of Deltrex-1 (DTX1) gene 
was correlated with increased cell migration and invasion,21 while over-expression of SLC7A7 
predicts poor PFS and OS in patients with GBM.22DNA molecular data for the patients in this 
study at the time of data collection were not available, and retrospective analysis was not 
possible because of HIPAA rules and the requirement to destroy the samples after death.  
Research suggests that human cytomegalovirus (HCMV) infection plays a role in 
survival.23 Patients with GBM who had low grade HCMV infection had increased survival and 
time to progression compared to moderate and high grade infection. This data was also not 
available in this study.  
Additionally, newer studies about surgical resection and survival in GBM have evaluated 
a new technology consistent of fluorescence guided resection. Research suggests that complete 
surgical resection of the enhancing tumor on early MRI and no fluorescent residual tissue can 
have longer OS compared to those with residual fluorescent tissue,24 but this technology was not 
available for our sample to be evaluated.  
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Conclusions 
This study suggests that there may be an advantage for a longer duration of TMZ therapy 
in patients with GBM.  In this review, treatment with TMZ for two years was associated with an 
increased survival benefit, regardless of age, a higher KPS score or a total initial resection. 
Furthermore, a right sided brain GBM may have a survival advantage over a left sided brain 
GBM. Despite the lack of basic science data, the results of this study seem to be worthy of 
further evaluation with a prospective large sample study. 
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Figure 1: Flow Diagram of the Study Sample 
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Figure 2: Overall Survival  
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Figure 3: Progression-Free Survival 
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Figure 4: Overall Survival by Treatment Duration 
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Figure 5: Overall Survival by Karnofsky’s Performance Score 
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Figure 6: Overall Survival by Brain Hemisphere Location of the Tumor 
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Figure 7: Overall Survival by Surgical Resection 
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Figure 8: Overall Survival by Progression of Tumor 
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Figure 9: Overall Survival by Gender 
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Figure 10: Overall Survival by Lobar Location of the Tumor 
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Figure 11: Overall Survival by Pathology Review 
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Figure 12: Overall Survival by Anti-Convulsive Treatment 
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Figure 13: Overall Survival by Type of Anti-Convulsive Treatment Used 
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Figure 14: Overall Survival by Age-group 
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